New Strategy for Unmet Need in Relapsed/Refractory DLBCL

During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

The field of Hodgkin lymphoma is undergoing significant advancements, with new drugs entering the frontline and personalized treatment approaches emerging.

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.

Golcadomide plus R-CHOP was well tolerated and demonstrated high metabolic response rates that were durable in patients with previously untreated a-BCL.